Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM-3 antibody, in combination with decitabine or azacitidine in high- or very high-risk myelodysplastic syndromes

Andrew M. Brunner; Jordi Esteve; Kimmo Porkka; Steve Knapper; Elie Traer; Sebastian Scholl; Guillermo Garcia-Manero; Norbert Vey; Martin Wermke; Jeroen J.W.M. Janssen; Rupa Narayan; Shaun Fleming; Sun Loo; Natalia Tovar; Mika Kontro; Oliver G. Ottmann; Purushotham Naidu; Haiying Sun; May Han; Roisin White; Na Zhang; Anisa Mohammed; Catherine A. Sabatos-Peyton; David P. Steensma; Mikael L. Rinne; Uma M. Borate; Andrew H. Wei

doi:10.1002/ajh.27161

Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM-3 antibody, in combination with decitabine or azacitidine in high- or very high-risk myelodysplastic syndromes

Andrew M. Brunner, Jordi Esteve, Kimmo Porkka, Steve Knapper, Elie Traer, Sebastian Scholl, Guillermo Garcia-Manero, Norbert Vey, Martin Wermke, Jeroen J.W.M. Janssen, Rupa Narayan, Shaun Fleming, Sun Loo, Natalia Tovar, Mika Kontro, Oliver G. Ottmann, Purushotham Naidu, Haiying Sun, May Han, Roisin WhiteNa Zhang, Anisa Mohammed, Catherine A. Sabatos-Peyton, David P. Steensma, Mikael L. Rinne, Uma M. Borate, Andrew H. Wei

Research output: Contribution to journal › Letter › Research › peer-review

4 Citations (Scopus)

Original language	English
Pages (from-to)	E32-E36
Number of pages	5
Journal	American Journal of Hematology
Volume	99
Issue number	2
DOIs	https://doi.org/10.1002/ajh.27161
Publication status	Published - Feb 2024
Externally published	Yes

Access to Document

10.1002/ajh.27161

Cite this

Brunner, A. M., Esteve, J., Porkka, K., Knapper, S., Traer, E., Scholl, S., Garcia-Manero, G., Vey, N., Wermke, M., Janssen, J. J. W. M., Narayan, R., Fleming, S., Loo, S., Tovar, N., Kontro, M., Ottmann, O. G., Naidu, P., Sun, H., Han, M., ... Wei, A. H. (2024). Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM-3 antibody, in combination with decitabine or azacitidine in high- or very high-risk myelodysplastic syndromes. American Journal of Hematology, 99(2), E32-E36. https://doi.org/10.1002/ajh.27161

@article{eb3fa64dfdcc42a49ac0bdcc88af686a,

title = "Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM-3 antibody, in combination with decitabine or azacitidine in high- or very high-risk myelodysplastic syndromes",

author = "Brunner, {Andrew M.} and Jordi Esteve and Kimmo Porkka and Steve Knapper and Elie Traer and Sebastian Scholl and Guillermo Garcia-Manero and Norbert Vey and Martin Wermke and Janssen, {Jeroen J.W.M.} and Rupa Narayan and Shaun Fleming and Sun Loo and Natalia Tovar and Mika Kontro and Ottmann, {Oliver G.} and Purushotham Naidu and Haiying Sun and May Han and Roisin White and Na Zhang and Anisa Mohammed and Sabatos-Peyton, {Catherine A.} and Steensma, {David P.} and Rinne, {Mikael L.} and Borate, {Uma M.} and Wei, {Andrew H.}",

note = "Funding Information: Medical writing support was provided by Bridget Sackey‐Aboagye, PhD, of Healthcare Consultancy Group, and was funded by Novartis Pharmaceuticals Corporation. ",

year = "2024",

month = feb,

doi = "10.1002/ajh.27161",

language = "English",

volume = "99",

pages = "E32--E36",

journal = "American Journal of Hematology",

issn = "0361-8609",

publisher = "John Wiley & Sons",

number = "2",

}

Brunner, AM, Esteve, J, Porkka, K, Knapper, S, Traer, E, Scholl, S, Garcia-Manero, G, Vey, N, Wermke, M, Janssen, JJWM, Narayan, R, Fleming, S, Loo, S, Tovar, N, Kontro, M, Ottmann, OG, Naidu, P, Sun, H, Han, M, White, R, Zhang, N, Mohammed, A, Sabatos-Peyton, CA, Steensma, DP, Rinne, ML, Borate, UM & Wei, AH 2024, 'Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM-3 antibody, in combination with decitabine or azacitidine in high- or very high-risk myelodysplastic syndromes', American Journal of Hematology, vol. 99, no. 2, pp. E32-E36. https://doi.org/10.1002/ajh.27161

Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM-3 antibody, in combination with decitabine or azacitidine in high- or very high-risk myelodysplastic syndromes. / Brunner, Andrew M.; Esteve, Jordi; Porkka, Kimmo et al.
In: American Journal of Hematology, Vol. 99, No. 2, 02.2024, p. E32-E36.

Research output: Contribution to journal › Letter › Research › peer-review

TY - JOUR

T1 - Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM-3 antibody, in combination with decitabine or azacitidine in high- or very high-risk myelodysplastic syndromes

AU - Brunner, Andrew M.

AU - Esteve, Jordi

AU - Porkka, Kimmo

AU - Knapper, Steve

AU - Traer, Elie

AU - Scholl, Sebastian

AU - Garcia-Manero, Guillermo

AU - Vey, Norbert

AU - Wermke, Martin

AU - Janssen, Jeroen J.W.M.

AU - Narayan, Rupa

AU - Fleming, Shaun

AU - Loo, Sun

AU - Tovar, Natalia

AU - Kontro, Mika

AU - Ottmann, Oliver G.

AU - Naidu, Purushotham

AU - Sun, Haiying

AU - Han, May

AU - White, Roisin

AU - Zhang, Na

AU - Mohammed, Anisa

AU - Sabatos-Peyton, Catherine A.

AU - Steensma, David P.

AU - Rinne, Mikael L.

AU - Borate, Uma M.

AU - Wei, Andrew H.

N1 - Funding Information: Medical writing support was provided by Bridget Sackey‐Aboagye, PhD, of Healthcare Consultancy Group, and was funded by Novartis Pharmaceuticals Corporation.

PY - 2024/2

Y1 - 2024/2

UR - http://www.scopus.com/inward/record.url?scp=85177585116&partnerID=8YFLogxK

U2 - 10.1002/ajh.27161

DO - 10.1002/ajh.27161

M3 - Letter

C2 - 37994196

AN - SCOPUS:85177585116

SN - 0361-8609

VL - 99

SP - E32-E36

JO - American Journal of Hematology

JF - American Journal of Hematology

IS - 2

ER -

Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM-3 antibody, in combination with decitabine or azacitidine in high- or very high-risk myelodysplastic syndromes

Access to Document

Other files and links

Cite this